Plans Advancing for Trial of Elamipretide in Aiding Cardiac Muscle in DMD

A branch of the U.S. Food and Drug Administration (FDA) known as the Division of Cardiology and Nephrology has given positive feedback to Stealth BioTherapeutics‘ program for Duchenne muscular dystrophy (DMD). In a pre-investigational new drug (pre-IND) meeting, the division — called the DCN — agreed to the design of…